Hikma Pharmaceuticals Plc HIK

Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in the United States, Europe, and the UK. Hikma has also filed a submission for its epinephrine nasal spray in Canada, with plans to expand filings beyond these markets in due course.

Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in execution and valuation, although they also flag sensitivity to assumptions that could work against the stock if conditions change. As you read on, you will see how to interpret this evolving narrative and what to watch as new research comes...

Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share...

Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no longer justified. Ephrem Ravi reiterated a buy rating and set a new price target of...

Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma delivered a substantial beat at the half-year stage, driven primarily by the branded division,...

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The scale of the beat is the story. Core operating profit rose 8.6% to $405 million, roughly 11%...

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has already rebounded 30% from its lows but Panmure Liberum believes the generic drugmaker still offers upside if it can rebuild investor confidence following last year's profit warning. The broker retained its 'buy' rating and 1,600p price...

Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry point. The 12-month target, based on a sum-of-the-parts valuation, implies a share price return...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, T

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

Gov. Mike DeWine announced eight projects bringing jobs and investment to cities across Ohio.

Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio – Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced plans for a significant expansion of Hikma’s manufacturing operations in Ohio, reinforcing the company’s commitment to the state’s growing pharmaceutical and biomanufacturing industry. A leading U.S. generic medication provider, Hikma will invest a total of $26

Hikma Pharmaceuticals has seen its model fair value edge from £18.84 to £18.74 per share, alongside reduced Street price targets such as 1,800 GBp from 2,300 GBp and 2,000 GBp from 2,400 GBp. Analysts, including JPMorgan with its Overweight rating and revised targets in the £18.00 to £20.00 range, are reframing the story as a valuation reset rather than a change in their overall view. As you read on, you will see how to interpret these shifting targets and keep up with the evolving Hikma...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infringement litigation regarding VYNDAMAX (tafamidis). These agreements effectively extend Pfizer’s US patent protection for the transthyretin-mediated amyloidosis (ATTR-CM) treatment […]

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.